Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
How I monitor residual disease in chronic myeloid leukemia
Beteiligte:
Radich, Jerald P.
Erschienen:
American Society of Hematology, 2009
Erschienen in:
Blood, 114 (2009) 16, Seite 3376-3381
Sprache:
Englisch
DOI:
10.1182/blood-2009-02-163485
ISSN:
0006-4971;
1528-0020
Entstehung:
Anmerkungen:
Beschreibung:
Abstract Molecular monitoring in chronic myeloid leukemia (CML) is a powerful tool to document treatment responses and predict relapse. Nonetheless, the proliferation of clinical trials and “guidelines” using the molecular endpoints of CML has outpaced practice norms, commercial laboratory application, and reimbursement practices, leaving some anxiety (if not confusion and despair) about molecular monitoring in the day-to-day treatment of CML. This article will try to address these issues by describing how I monitor CML, which, in summary, is with interest and without panic.